Earnings Summary

Harmony Biosciences Holdings Inc’s revenue jumped 36.74% since last year same period to $160.27Mn in the Q3 2023. On a quarterly growth basis, Harmony Biosciences Holdings Inc has generated 19.41% jump in its revenue since last 3-months.

Harmony Biosciences Holdings Inc’s net profit fell -56.27% since last year same period to $38.46Mn in the Q3 2023. On a quarterly growth basis, Harmony Biosciences Holdings Inc has generated 12.13% jump in its net profits since last 3-months.

Harmony Biosciences Holdings Inc’s net profit margin fell -68.02% since last year same period to 24% in the Q3 2023. On a quarterly growth basis, Harmony Biosciences Holdings Inc has generated -6.1% fall in its net profit margins since last 3-months.

Harmony Biosciences Holdings Inc’s price-to-earnings ratio after this Q3 2023 earnings stands at 12.7.

Harmony Biosciences Holdings Inc’s earning per share (EPS) estimates for the current quarter stand at 0.58 - a -10.77% fall from last quarter’s estimates.

Harmony Biosciences Holdings Inc’s earning per share (EPS) estimates for the current year stand at 0.58.

Harmony Biosciences Holdings Inc’s earning per share (EPS) fell -47.92% since last year same period to 0.75 in the Q3 2023. This indicates that the Harmony Biosciences Holdings Inc has generated -47.92% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Harmony Biosciences Holdings Inc’s return on assets (ROA) stands at 0.18.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Harmony Biosciences Holdings Inc’s return on equity (ROE) stands at 0.37.